SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-007474
Filing Date
2024-05-09
Accepted
2024-05-09 08:01:31
Documents
15
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K viri-20240509x8k.htm   iXBRL 8-K 41948
2 EX-99.1 viri-20240509xex99d1.htm EX-99.1 106650
3 GRAPHIC viri-20240509xex99d1001.jpg GRAPHIC 11583
  Complete submission text file 0001558370-24-007474.txt   294193

Data Files

Seq Description Document Type Size
4 EX-101.SCH viri-20240509.xsd EX-101.SCH 3114
5 EX-101.LAB viri-20240509_lab.xml EX-101.LAB 15918
6 EX-101.PRE viri-20240509_pre.xml EX-101.PRE 10045
18 EXTRACTED XBRL INSTANCE DOCUMENT viri-20240509x8k_htm.xml XML 4803
Mailing Address 44 MILTON AVENUE ALPHARETTA GA 30009
Business Address 44 MILTON AVENUE ALPHARETTA GA 30009 8666208655
Virios Therapeutics, Inc. (Filer) CIK: 0001818844 (see all company filings)

IRS No.: 854314201 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39811 | Film No.: 24928683
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)